SAGA Diagnostics AB news
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?
SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in minimally-invasive “liquid biopsies” su
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN).
SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR assays towards undisclosed methylated targe
SAGA Diagnostics AB, (“SAGA”), a leading cancer liquid biopsy and genomic testing company, is pleased to announce the appointment of Peter Collins as Chief Executive Officer.
Mr. Collins is a highly experienced entrepreneur with over 30 years of experience in the pharma and diagnostics sector.
He joins SAGA after successful executive roles at major players in the liquid
SAGA Diagnostics AB, “SAGA”, a leading cancer liquid biopsy and genomic testing company, adapted a SAGAsafe® PIK3CA 24-plex mutation detection assay to work on Stilla Technologies’ new naica® Prism 6 system which was presented at this year’s Annual Meeting of the American Society of Human Genetics (ASHG) on October 14. Chief Operating Officer Dr. Lao Saal, MD PhD,
SAGA Diagnostics AB (“SAGA”), a cancer liquid biopsy and genomic testing company, today announced that it has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led by Segulah Medical Acceleration and the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.
SAGA is commercializing proprietary technologies to quantify cancer-as